France Viscosupplementation Market Size & Outlook
France viscosupplementation market, 2018-2030 (US$M)
Related Markets
France viscosupplementation market highlights
- The France viscosupplementation market generated a revenue of USD 129.0 million in 2023 and is expected to reach USD 270.0 million by 2030.
- The France market is expected to grow at a CAGR of 11.1% from 2024 to 2030.
- In terms of segment, single injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
Viscosupplementation market data book summary
| Market revenue in 2023 | USD 129.0 million |
| Market revenue in 2030 | USD 270.0 million |
| Growth rate | 11.1% (CAGR from 2023 to 2030) |
| Largest segment | Single injection |
| Fastest growing segment | Single Injection |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, France accounted for 2.7% of the global viscosupplementation market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, France viscosupplementation market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 270.0 million by 2030.
Single injection was the largest segment with a revenue share of 43.18% in 2023. Horizon Databook has segmented the France viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of osteoarthritis is expected to increase in France due to increasing proportion of elderly population. The overall social and demographical changes have resulted in increased healthcare burden on the country, forcing it to reduce the healthcare budget. In 2014, there were more than 12 HA derivatives are on the market, classified as devices, except in the case of Hyalgan, which has been classified as a drug with market authorization in knee osteoarthritis.
In 2000, Biomatrix reported that the Ministère de l' Emploi et de la Solidarité, France Ministry of Health agreed to reimburse the high-molecular-weight viscoelastic devices with three intraarticular injections administered for over a 15-day period. There are various manufacturers operating in the market who are in the process of introducing new products.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France viscosupplementation market size, by product, 2018-2030 (US$M)
France Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
